NEW YORK (Genomeweb News) – Shares of Millipore were up 4 percent at $69.02 in afternoon trade on the New York Stock Exchange after an upgrade to its rating by investment bank Leerink Swann.

The bank raised its rating on Millipore to "outperform" from "market perform." Analyst Isaac Ro said that the change was due to "improving fundamentals and execution."

Millipore "should benefit from exposure to a number of themes that include cell-based H1N1 vaccine production, an improving biologics pipeline, recent product launches, and stimulus funding," wrote Ro.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.